Millipore Sigma Vibrant Logo
Home>Biopharmaceutical Manufacturing>BioReliance® Product Characterization Services

BioReliance® Product Characterization Services

Ask us a question
Cell Line Development Interlot & Biosimilar Comparability Lot Release & Stability Process & Product Impurities Antibody Drug Conjugates

Assay Packages: Lot Release and Stability Testing

0 1 2 3 4 5 Days

Before your mAb therapy reaches a patient, it is important to ensure product safety and efficacy. This includes understanding the effects of environmental conditions - temperature, humidity, light, container interactions – on your mAb. We offer a full portfolio of lot release and stability testing services performed to GMP guidelines. While others may provide data points, we combine full data with regulatory guidance required for clinical submission. We partner with you to develop a customized lot release program at every stage of biotherapeutic development:

  • Raw Materials
  • Unprocessed Bulk
  • Purified Bulk (Drug Substance)
  • Final Product (Drug Product)
  • mAb Stability Package
Ideal during:
Phase I
Phase II
Phase III

Assay families that satisfy testing needs include:

  • Physical testing

    Used to characterize the appearance of a mAb, for example through high accuracy (HIAC) particulate analysis, physical testing includes measurement of pH, osmolality and concentration. Packaging integrity is also assessed within physical testing protocol, for example using Karl Fischer moisture analysis or dye ingress to confirm closure integrity.

  • Identification testing

    To confirm that your mAb product is what you think it is, it’s important to perform intact mass (IM) analysis, amino acid analysis, glycan profiling, and sequence mapping. Higher order structure (HOS) can also be evaluated.

  • Product impurity testing

    The presence of impurities in your mAb product can present a serious risk and prevent regulatory approval. Techniques such as dynamic light scattering (DLS) and UHPLC ion exchange, used to check for size variants and charge variants respectively, provide essential data to support your clinical submission.

  • Potency / binding testing

    The efficacy of your mAb hinges on its affinity for the target. Many different methods can be used to evaluate this, including Fc gamma receptor and C1q binding assays, specific measurement of target antigen affinity, and various cell-based assays such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) to qualify mAb potency.

  • Microbiology testing

    To ensure your mAb’s quality and safety, several tests are essential to meet regulatory requirements. These include bioburden determination, bacterial endotoxin testing, and sterility testing, all of which are necessary to confirm product integrity.

  • Process impurity / residual testing

    Impurities generated during the mAb production process can slow a mAb’s ability to move through the regulatory approval process. Rigorous monitoring is necessary to detect detergent or surfactant left behind during manufacturing, while the presence of residual protein and DNA also requires thorough evaluation.

Hear from Our Experts

Get insight into topics that directly impact your success to clinic. Learn more from our white papers, videos, webinars, and posters.

Knowledge Center

Contact Us

Contact our product characterization experts to discuss your specialized needs and take the next step to securing the future of your biotherapy.

Ask Us a Question Connect with Us on LinkedIn